Evidence map›Paper›PMID 36038915›Full record

ReviewCell communication and signaling : CCS2022

Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives.

Mohammad Sadegh Soltani-Zangbar, Forough Parhizkar, Mojtaba Abdollahi, Navid Shomali, Leili Aghebati-Maleki, Sima Shahmohammadi Farid, Leila Roshangar, Ata Mahmoodpoor, Mehdi Yousefi

Open access · goldAbstract readReviewVideo-Audio Media
In one paragraph

Review in Cell communication and signaling : CCS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Carbon quantum dots in bioimaging and biomedicines.Frontiers in bioengineering and biotechnology · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mohammad Sadegh Soltani-Zangbar *Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Forough Parhizkar *Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Mojtaba AbdollahiSchool of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Navid ShomaliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Leili Aghebati-MalekiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sima Shahmohammadi FaridDepartment of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Leila RoshangarStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ata MahmoodpoorDepartment of Anesthesiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi YousefiStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. mehdi_yusefi@yahoo.com.
Tabriz University of Medical Sciences · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During SARS-CoV-2 infection, an effective immune response provides the first line of defense; however, excessive inflammatory innate immunity and impaired adaptive immunity may harm tissues. Soluble immune mediators are involved in the dynamic interaction of ligands with membrane-bound receptors to maintain and restore health after pathological events. In some cases, the dysregulation of their expression can lead to disease pathology. In this literature review, we described current knowledge of the basic features of soluble immune mediators and their dysregulation during SARS-CoV-2 infections and highlighted their contribution to disease severity and mortality. Video Abstract.

Indexed as

COVID-19Adaptive ImmunityHumansImmune SystemImmunity, InnateSARS-CoV-2COVID-19SARS-CoV-2Soluble immune checkpointsSoluble immune mediator

Identifiers

PMID36038915
PMCPMC9421625
OpenAlexW4293441871

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.